Fig. 3
From: Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
Pairwise quantification (Bland-Altman plots) of the limits of agreement (LOAs, dashed lines) of the relative AD difference for the alternative dosimetry protocols (B–I). The AD/cycle from each method is compared to that of method P (hybrid dosimetry in every treatment cycle, as per protocol) and normalized to the mean of the two methods. B: Planar dosimetry first cycle only (2SD = 51%). C: Planar dosimetry in all cycles (2SD = 43%). D: Hybrid dosimetry first cycle only (2SD = 36%). E: Hybrid dosimetry cycle one, and one SPECT/CT at 24 h in the following cycles (2SD = 17%). F: One SPECT/CT at 24 h in each cycle and constant half-time (2SD = 25%). Methods G, H and I are all based on Eq. 8 (see the “Methods” section). G: One SPECT/CT at 96 h in all cycles (2SD = 11%). H: One SPECT/CT at 96 h first cycle only (2SD = 39%). I: Planar dosimetry at 96 h in all cycles (2SD = 45%)